Apyx Medical (APYX) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Apyx Medical (APYX) overview

Apyx Medical (APYX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 52.8m and operating profit of USD -6.4m; the year-end share price was 3.50 USD and market capitalisation was USD 146m. Apyx Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Apyx Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 14.5mFY 2025
Share price3.50 USDFY 2025 year end
RevenueUSD 52.8mFY 2025
Operating profitUSD -6.4mFY 2025
Net earningsUSD -11.2mFY 2025
Market capitalisationUSD 146mFY 2025 year end

About Apyx Medical

Apyx Medical develops and sells surgical products for cosmetic surgery and hospital procedures. Its Helium Plasma Platform Technology products are marketed as Renuvion and J-Plasma, which provide surgeons with controlled heat for tissue treatment. Its AYON Body Contouring System combines fat removal, contouring, tissue contraction, and electrosurgical capabilities. The company also provides waveform expertise to other medical device manufacturers through OEM agreements.

Generate the Apyx Medical report

Apyx Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Apyx Medical and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Apyx Medical

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.